CA2578402A1 - Inhibition du papillomavirus humain a l'aide d'un ribozyme en forme d'e ingle a cheveux - Google Patents
Inhibition du papillomavirus humain a l'aide d'un ribozyme en forme d'e ingle a cheveux Download PDFInfo
- Publication number
- CA2578402A1 CA2578402A1 CA002578402A CA2578402A CA2578402A1 CA 2578402 A1 CA2578402 A1 CA 2578402A1 CA 002578402 A CA002578402 A CA 002578402A CA 2578402 A CA2578402 A CA 2578402A CA 2578402 A1 CA2578402 A1 CA 2578402A1
- Authority
- CA
- Canada
- Prior art keywords
- ribozyme
- seq
- hpv
- sequence
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000701806 Human papillomavirus Species 0.000 title claims abstract description 55
- 108090001052 hairpin ribozyme Proteins 0.000 title claims description 28
- 230000005764 inhibitory process Effects 0.000 title description 3
- 108090000994 Catalytic RNA Proteins 0.000 claims abstract description 204
- 102000053642 Catalytic RNA Human genes 0.000 claims abstract description 204
- 108091092562 ribozyme Proteins 0.000 claims abstract description 204
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 69
- 230000007017 scission Effects 0.000 claims abstract description 67
- 241000341655 Human papillomavirus type 16 Species 0.000 claims abstract description 49
- 239000012634 fragment Substances 0.000 claims description 51
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 49
- 239000013598 vector Substances 0.000 claims description 47
- 210000004027 cell Anatomy 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 41
- 108020004414 DNA Proteins 0.000 claims description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 230000000295 complement effect Effects 0.000 claims description 10
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 8
- 201000010881 cervical cancer Diseases 0.000 claims description 8
- 239000002299 complementary DNA Substances 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 229960004316 cisplatin Drugs 0.000 claims description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 5
- 229940127089 cytotoxic agent Drugs 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 239000000677 immunologic agent Substances 0.000 claims description 4
- 229940124541 immunological agent Drugs 0.000 claims description 4
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 claims description 3
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 claims description 3
- 241000709701 Human poliovirus 1 Species 0.000 claims 1
- 208000006994 Precancerous Conditions Diseases 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 238000003556 assay Methods 0.000 abstract description 11
- 230000003612 virological effect Effects 0.000 abstract description 10
- 238000012408 PCR amplification Methods 0.000 abstract description 2
- 239000000758 substrate Substances 0.000 description 51
- 239000013612 plasmid Substances 0.000 description 47
- 238000006243 chemical reaction Methods 0.000 description 31
- 239000003054 catalyst Substances 0.000 description 29
- 108020004999 messenger RNA Proteins 0.000 description 21
- 239000000523 sample Substances 0.000 description 20
- 239000000047 product Substances 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 16
- 238000013518 transcription Methods 0.000 description 15
- 230000035897 transcription Effects 0.000 description 15
- 241000894007 species Species 0.000 description 14
- 238000003752 polymerase chain reaction Methods 0.000 description 12
- 230000003197 catalytic effect Effects 0.000 description 11
- 238000012986 modification Methods 0.000 description 11
- 230000004048 modification Effects 0.000 description 11
- 230000001177 retroviral effect Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 10
- 108010083644 Ribonucleases Proteins 0.000 description 9
- 102000006382 Ribonucleases Human genes 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 108091026890 Coding region Proteins 0.000 description 8
- 230000000692 anti-sense effect Effects 0.000 description 8
- 238000011144 upstream manufacturing Methods 0.000 description 8
- 101100441542 Cryptococcus neoformans var. neoformans serotype D (strain JEC21 / ATCC MYA-565) CXT1 gene Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 150000007513 acids Chemical class 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 101710137500 T7 RNA polymerase Proteins 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000012933 kinetic analysis Methods 0.000 description 6
- 238000010369 molecular cloning Methods 0.000 description 6
- 238000010839 reverse transcription Methods 0.000 description 6
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 6
- 241001430294 unidentified retrovirus Species 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 241000251131 Sphyrna Species 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000007306 turnover Effects 0.000 description 4
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000000370 acceptor Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 229940063673 spermidine Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- FDUNZPWFWGRHOM-UHFFFAOYSA-N 5'ggacuucggucc-3 Chemical compound O=C1N=C(N)C=CN1C1OC(COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C=C2)=O)COP(O)(=O)OC2C(C(OC2COP(O)(=O)OC2C(C(OC2COP(O)(=O)OC2C(C(OC2COP(O)(=O)OC2C(C(OC2CO)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=NC=NC(N)=C3N=C2)O)N2C(N=C(N)C=C2)=O)O)C(OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(C(O)C(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)OP(O)(=O)OCC2C(C(O)C(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(C(O)C(O2)N2C(N=C(N)C=C2)=O)O)C1 FDUNZPWFWGRHOM-UHFFFAOYSA-N 0.000 description 2
- 206010059313 Anogenital warts Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 208000009608 Papillomavirus Infections Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010078067 RNA Polymerase III Proteins 0.000 description 2
- 102000014450 RNA Polymerase III Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000013643 reference control Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 101100540311 Human papillomavirus type 16 E6 gene Proteins 0.000 description 1
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000010310 bacterial transformation Effects 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 206010006060 bowenoid papulosis Diseases 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- -1 i.e. Proteins 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 102220049129 rs139102191 Human genes 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000017015 squamous papilloma Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24266594A | 1994-05-13 | 1994-05-13 | |
| US08/242,665 | 1994-05-13 | ||
| CA002190102A CA2190102A1 (fr) | 1994-05-13 | 1995-05-15 | Inhibition du papillomavirus humain a l'aide d'un ribozyme en forme d'epingle a cheveux |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002190102A Division CA2190102A1 (fr) | 1994-05-13 | 1995-05-15 | Inhibition du papillomavirus humain a l'aide d'un ribozyme en forme d'epingle a cheveux |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2578402A1 true CA2578402A1 (fr) | 1995-11-23 |
Family
ID=37965278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002578402A Abandoned CA2578402A1 (fr) | 1994-05-13 | 1995-05-15 | Inhibition du papillomavirus humain a l'aide d'un ribozyme en forme d'e ingle a cheveux |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2578402A1 (fr) |
-
1995
- 1995-05-15 CA CA002578402A patent/CA2578402A1/fr not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1995031552A2 (fr) | Inhibition du papillomavirus humain a l'aide d'un ribozyme en forme d'epingle a cheveux | |
| EP0748383B1 (fr) | Clivage cible de l'arn par ciblage de la ribonuclease p et sequences de clivage | |
| AU702373B2 (en) | Stabilized external guide sequences | |
| JP3015463B2 (ja) | 真核リボヌクレアーゼｐを用いるｒｎａの標的化切断および外部ガイド配列 | |
| Ojwang et al. | Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. | |
| EP0894129B1 (fr) | Sequence guides externes courtes | |
| CA2433680A1 (fr) | Suppression de gene mediee par arn bicatenaire | |
| WO1995004818A1 (fr) | Procede et reactif servant a inhiber la replication du virus de l'immunodeficience humaine | |
| Kiehntopf et al. | Ribozymes: biology, biochemistry, and implications for clinical medicine | |
| US6277980B1 (en) | Human papilloma virus inhibition by anti-sense oligonucleotides | |
| WO2007052046A1 (fr) | Acide nucleique des ribozymes anti-virus de l'hepatite b | |
| US6656731B1 (en) | Nucleic acid catalysts with endonuclease activity | |
| EP0759992B1 (fr) | Inhibition du papillomavirus humain a l'aide d'un ribozyme en forme d'epingle a cheveux | |
| CA2578402A1 (fr) | Inhibition du papillomavirus humain a l'aide d'un ribozyme en forme d'e ingle a cheveux | |
| Rossi | Therapeutic ribozymes: principles and applications | |
| MXPA96005514A (en) | Horqui medianteribozima human papilloma virus inhibition | |
| WO2004027044A2 (fr) | Ribozyme en epingle a cheveux triplex | |
| CA2236998C (fr) | Ribozymes specifiques de tissus ou d'arn cible | |
| WO1995022600A1 (fr) | Therapie ribozymique de l'infection par le virus de l'hepatite b | |
| AU9825398A (en) | Method and reagent for inhibiting human immunodeficiency virus replication | |
| Rossi et al. | [19] Ribozymes as therapeutic agents and tools for gene analysis | |
| AU2002300399A8 (en) | Human papilloma virus inhibition by anti-sense oligonucleotides | |
| AU7375594A (en) | Method and reagent for inhibiting human immunodeficiency virus replication | |
| EP0716693A1 (fr) | Procede et reactif servant a inhiber la replication du virus de l'immunodeficience humaine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |